Title

The causal role of accelerometer-derived sleep traits on glycated haemoglobin: a Mendelian randomization study

Authors

Junxi Liu*Ω[1, 2], Rebecca C Richmond*[1, 2], Emma L Anderson[1,2], Jack Bowden[3, 1], Ciarrah-Jane S Barry[1, 2], Hassan S Dashti [4, 5, 6], Iyas S Daghlas[4, 5, 6], Jacqueline M Lane[4, 5, 6], Simon D Kyle[7], Céline Vetter[8], Claire L Morrison[9], Samuel E Jones[10], Andrew R Wood[11], Timothy M Frayling[11], Alison K Wright[12], Matthew J Carr[12, 13, 14], Simon G Anderson[15, 16], Richard A Emsley[17], David W Ray[18, 19], Michael N Weedon[11], Richa Saxena[4, 5, 6, 20], Martin K Rutter[†13, 21,22] Deborah A Lawlor[†1, 2, 24]

* = Joint first authors, with equal contributions; [†] = Joint senior authors, with equal contributions.

Ω Corresponding author:

Dr. Junxi Liu

MRC Integrative Epidemiology Unit, Bristol Medical School, University of Bristol

Oakfield House, Oakfield Grove, Clifton, Bristol, BS8 2BN

Email: ieu_james.liu@bristol.ac.uk

Affiliations:

1. MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK

2. Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK

3. College of Medicine and Health, the University of Exeter, Exeter, UK

4. Centre for Genomic Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

5. Broad Institute of MIT and Harvard, Cambridge, MA, USA

6. Department of Anaesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA, USA

7. Sir Jules Thorn Sleep and Circadian Neuroscience Institute, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.

8. Department of Integrative Physiology, University of Colorado Boulder, Boulder, CO, United States

9. Department of Psychology & Neuroscience and Institute for Behavioral Genetics, University of Colorado Boulder, Boulder, CO, USA

10. Institute for Molecular Medicine Finland, University of Helsinki, Uusimaa, Finland

11. Genetics of Complex Traits, University of Exeter Medical School, Exeter, UK

12. Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK

13. Manchester Academic Health Science Centre, University of Manchester, Manchester, UK

14. National Institute for Health Research (NIHR) Greater Manchester Patient Safety Translational Research Centre, University of Manchester, UK

15. George Alleyne Chronic Disease Research Centre, Caribbean Institute of Health Research, University of the West Indies, Kingston, Jamaica

16. Division of Cardiovascular Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, UK

17. Department of Biostatistics and Health Informatics, King's College London, London, UK

18. National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford UK

19. Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford UK

20. Division of Sleep and Circadian Disorders, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

21. Diabetes, Endocrinology and Metabolism Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, Manchester, UK

22. Division of Diabetes, Endocrinology and Gastroenterology, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK

24. National Institute for Health Research (NIHR) Bristol Biomedical Research Centre, University Hospitals Bristol NHS Foundation Trust and the University of Bristol, Bristol, UK

Abstract

Self-reported (SR) shorter/longer sleep duration, insomnia, and evening preference are associated with hyperglycaemia in observational analyses, with similar results observed in small studies using accelerometer-derived (AcD) sleep traits. Mendelian randomization (MR) studies support an effect of SR insomnia, but not other sleep traits, on glycated haemoglobin (HbA1c). We used MR to explore effects of AcD sleep traits (duration, mid-point least active 5-hours, mid-point most active 10-hours, sleep fragmentation, and efficiency) on HbA1c in European adults from the UK Biobank (UKB) (n = 73,797) and the MAGIC consortium (n = 149,054). Main and sensitivity MR analyses showed no causal effect of any AcD sleep trait on HbA1c. Similar MR results for SR sleep traits in the UKB sub-sample with AcD measures suggested our results were not explained by selection bias. Genetic correlation analyses suggested complex relationships between SR and AcD traits indicating that they may reflect different types of exposure.

Introduction

Achieving healthy sleep is necessary for physical and mental health. Sleep disturbance has been associated with type 2 diabetes (T2D).[1-3] Identifying causal effects of sleep characteristics on diabetes could support the development of new interventions designed to prevent and/or treat T2D.

Prospective cohort studies have identified associations of self-reported (SR) short and long sleep duration, insomnia (difficulty initiating or maintaining sleep), and chronotype (evening preference) with higher risks of T2D,[1-3] hyperglycaemia and insulin resistance.[4,5] A small number of studies have assessed sleep characteristics using accelerometry devices, assuming these reflect similar sleep characteristics measured with greater precision and less measurement error than SR traits. Several observational studies have shown that accelerometer-derived (AcD) shorter sleep duration and lower sleep efficiency (an assumed indicator of insomnia[6]) were associated with higher glycated haemoglobin (HbA1c) levels in people with diabetes.[7,8] In a non-clinical general population cohort, who completed home sleep apnea testing, higher sleep fragmentation[9] (also a potential indicator of insomnia[10]), but not shorter AcD sleep duration,[11] was associated with higher levels of HbA1c and glucose. However, these were relatively small studies that included ~170[7] to ~2107[11] participants, and due to their observational nature, these associations could reflect residual confounding or reverse causation. A meta-analysis of randomized controlled trials has shown that interventions reducing sleep duration had detrimental effects on insulin sensitivity in healthy individuals.[12] Other experimental data in healthy volunteers have suggested that sleep restriction leads to hyperglycaemia,[13] but the relevance of experimental sleep restriction protocols to the sleep patterns experienced in the general population is unclear.

Mendelian randomization (MR) is increasingly used to explore lifelong causal effects because it is less prone to confounding by social, environmental, and behavioural factors.[14] Previous MR studies, by us and others, have shown that SR frequent insomnia symptoms have a role in causing higher HbA1c,[15-17] whilst no evidence has been provided for an effect of SR sleep duration or chronotype on T2D and/or related

glycaemic traits.[15,18-20] An MR study in the UK Biobank (UKB) also suggested no causal effect of AcD sleep duration on T2D.[20] Besides, there was MR evidence that shorter AcD sleep duration and lower sleep efficiency increased waist-hip ratio, but not T2D risk or other hyperglycaemic outcomes in the UKB.[21]

Our aim was to explore potential effects of AcD sleep traits (duration, mid-point least active 5-hours (L5 timing), mid-point most active 10-hours (M10 timing), sleep fragmentation, and sleep efficiency) on HbA1c, using MR. We undertook one-sample MR (1SMR) analyses using the UKB sub-sample with valid accelerometer measures, restricting analyses to participants of European ancestry (n = 73,797). Since those with accelerometer data were not a random sub-sample of UKB, we explored possible selection bias by re-running, in this sub-sample, all of our previous MR analyses of SR sleep traits (duration, chronotype, insomnia) with HbA1c that had been conducted in the larger UKB White British sample (n = 336,999).[15] Additionally, we conducted two-sample MR (2SMR) analyses using summary outcome data from UKB and the MAGIC consortium.[22] Lastly, to help understand any differences we observed between SR and AcD MR effects for assumed equivalent traits, we used cross-trait linkage disequilibrium score regression (LDSC)[23] to determine genetic correlations across all AcD and SR sleep traits. We also repeated all analyses with (non-fasting) glucose as a secondary outcome.

Results

Baseline characteristics

Figure 1 shows the flow of participants in the UKB sub-sample in which the 1SMR analyses were conducted (n = 73,797; European participants with AcD sleep measurements, HbA1c, and genome-wide single-nucleotide polymorphism (SNP) data). As the sub-sample with AcD measures were not randomly selected, we compared distributions of sociodemographic characteristics, SR sleep traits, and glycaemic traits between the sub-sample (n = 73,797) and (i) UKB European participants without AcD data (n = 306,317) and (ii) all UKB European participants with available genetic data (n = 385,163) (**Table 1**). Participants in the AcD sub-sample were more likely to have never smoked and have completed advanced-level education than those in either comparison group. The AcD sub-sample also had a lower prevalence of diagnosed diabetes, and diabetes defined as HbA1c levels >= 48 mmol/mol and had lower mean BMI. Other characteristics, including SR sleep traits were similar across the three groups (**Table 1**).

Figure 1. Flowchart of the participants included in the main analyses of effects of accelerometer-derived sleep traits on HbA1c in the UK Biobank.



* Quality control procedure undertaken, and the derived files produced by the MRC-IEU (University of Bristol), using the full UK Biobank genome wide SNP data (version 3, March 2018)https://data.bris.ac.uk/data/dataset/1ovaau5sxunp2cv8rcy88688v. The number of 79,460 was obtained after accounting for overlapped samples.
† Excluding participants with diabetes defined by the *Eastwood* algorithm (probable/possible type 1 diabetes and type 2 diabetes) and/or additionally those with a baseline HbA1c ≥ 48 mmol/mol.

Table 1. Baseline characteristics of European UK Biobank participants by the status of having accelerometer-derived sleep traits data.

Variable	Participants with accelerometer-derived sleep traits Mean (SD) / %	Participants without accelerometer-derived sleep traits* Mean (SD) / %	All available UKB participants with genetic data Mean (SD) / %
n	73,797	306,317	385,163
Age (years)	56.3 (7.8)	56.8 (8.1)	56.7 (8.0)
Female, Sex, %	56.0%	53.6%	54.0%
Body mass index (kg/m2)	26.7 (4.5)	27.6 (4.8)	27.4 (4.8)
Accelerometer-derived sleep traits			
Sleep duration, hour	7.29 (0.86)	-	-
Fragmentation / episode, times	17.2 (3.6)	-	-
Efficiency, %	76% (7%)	-	-
L5 timing, hour; time	27.3 (1.1); 3:18 a.m.	-	-
M10 timing, hour; time	13.7 (1.2); 1:42 p.m.	-	-
Self-reported sleep duration	7.2 (1.0)	7.2 (1.1)	7.2 (1.1)
Insomnia			
Never/rarely or sometimes, %	73%	71%	72%
Usually, %	27%	29%	28%
Chronotype			
Morning, %	23%	24%	24%
More 'morning' than 'evening', %	34%	32%	32%
Do not know, %	10%	10%	10%
More ''evening' ' than 'morning', %	25%	26%	26%
Evening, %	8%	8%	8%
HbA1c (mmol/mol) / log(hbA1c)	35.3 (5.5) / 3.55 (0.14)	36.1 (6.8) / 3.57 (0.15)	35.9 (6.5) / 3.57 (0.15)
HbA1c >= 48 mmol/l, %	2.3%	3.7%	3.4%
Glucose (mmol/L) / log(glucose)	5.1 (1.1) / 1.61 (0.16)	5.1 (1.2) / 1.62 (0.18)	5.1 (1.2) / 1.61 (0.17)
Diabetes defined by *Eastwood* algorithm, %	3.2%	5.0%	4.6%
Diagnosed sleep apnoea $, %	0.4%	0.5%	0.5%
Townsend deprivation index †	-1.8 (2.8)	-1.4 (3.1)	-1.5 (3.0)
Most affluent (the lowest 10%)	11%	10%	ref (<= -4.6)
Most deprived (the highest 10%)	7%	11%	ref (>= 3.1)
Smoking			
Never, %	56.7%	53.3%	54.0%
Former, %	36.5%	35.4%	35.6%
Current, %	6.8%	11.3%	10.4%
Alcohol intake ▯			
Daily, %	23.5%	20.7%	21.3%
One to four times a week, %	51.6%	49.6%	50.0%
One to three times a month, %	10.8%	11.2%	11.1%
Never / occasionally, %	14.1%	18.4%	17.6%
Education (ISCED codes)			
College or university degree / NVQ or HND or HNC or equivalent, %	58.3%	46.4%	48.8%
Other prof.equal. Eg: nursing, teaching, %	12.7%	12.1%	12.2%
A levels / AS levels or equivalent, %	6.3%	5.5%	5.7%
O levels / GCSEs or equivalent / CSEs or equivalent, %	14.6%	17.2%	16.7%
None of the above, %	8.1%	18.8%	16.6%
Days of vigorous physical activity per week ▯			
0 – 1 day, %	49.9%	52.1%	51.6%
2 -3 days, %	32.4%	29.0%	29.7%
4 – 7 days, %	17.7%	18.8%	18.6%

* The number of participants without AcD data (n = 306,317) is obtained via the whole European sample (n = 385,163) minus the number of raw AcD sample (n = 78,846, which had not accounted for activity-monitor data quality check).

† Townsend deprivation index was calculated using data from the preceding national census output areas, where each participant was assigned, a continuous score corresponding to the output area of their postcode location. A higher index indicates a greater level of deprivation.

▯ Alcohol intake was categorized and adjusted as "Daily", "One or four times a week", "Once or twice a week", "One to three times a month", "Occasionally", "Never"; vigorous physical activity was categorized as days from 0 to 7 per week. (Details in Supplementary Information)

$ Sleep apnea (ICD-10) was diagnosed from the Hospital Episode Statistics (HES) data.

Mendelian randomization results

In 1SMR analysis, genetic instrument – exposure and genetic instrument – outcome associations were estimated in the UKB sub-sample with AcD sleep data (n ~ 73,000). We generated unweighted allele scores for both AcD and SR sleep traits as the total number of adverse sleep trait increasing alleles present for each participant, based on SNPs identified in the relevant genome-wide association study (GWAS).[16,21,24,25] **Supplementary Table 1** provides details of each SNP. The variance (R^2) explained by the allele scores varied from 0.04% for M10 timing (F-statistic: 30) to 0.74% for sleep fragmentation (F-statistic: 553) among AcD traits, and from 0.54% for sleep duration (F-statistic: 401) to 2.12% for chronotype (F-statistic: 1593) among SR traits (**Supplementary Table 2**). F-statistic is related to R^2, sample size, and number of instruments, which indicates instrument strength. An F-statistic < 10 is usually considered as a weak instrument, which may introduce weak instrument bias.[26]

We conducted two sets of 2SMR analyses with the SNP – exposure associations for both of these analyses obtained from the relevant GWAS[16,21,24,25] as used for 1SMR, and the SNP – HbA1c associations were obtained from two different sources: i) SNP – HbA1c associations were estimated in UKB participants who did not participate in the AcD GWAS[21] study (referred to as 2SMR-UKB, n = ~292,000); ii) SNP – HbA1c associations were extracted from the MAGIC consortium GWAS[22] (referred to as 2SMR-MAGIC, n = ~149,000). The R^2 explained and the F-statistics for sleep traits were similar in these two data sources, ranging from 0.04% for M10 timing (mean F-statistic: 37) to 0.91% for sleep fragmentation (mean F-statistic: 37) among AcD traits, and from 0.68% for sleep duration (mean F-statistic: 40) to 2.78% for chronotype (mean F-statistic: 57) among SR traits (**Supplementary Table 2**).

1SMR suggested longer mean AcD sleep duration reduced mean HbA1c levels (-0.11, 95% CI: -0.22 to 0.01 SD per hour longer over 24-hours). However, the association was attenuated to the null in sensitivity analyses accounting for any possible horizontal pleiotropy (i.e., collider-correlated estimates[27]) in 1SMR; 2SMR main and sensitivity results provided no robust evidence of an effect of AcD sleep duration on

HbA1c (**Figures 2** and **Supplementary Table 3**). For all other AcD sleep traits, MR estimates (one-sample, two-sample, and their sensitivity analyses) did not support any evidence of causal effects on HbA1c (**Figures 2** and **Supplementary Table 3**). Results (1SMR and 2SMR-UKB) were broadly consistent when participants with diabetes were excluded (**Supplementary Table 3** and **4**). There was no evidence suggesting any effect of AcD sleep traits on glucose (**Supplementary Fig.1** and **Supplementary Table 4**).

In 1SMR, the associations of SR traits with HbA1c/glucose in the UKB sub-sample with AcD data (used here) were consistent, though with wider confidence intervals, with those we previously published using the larger samples[15] (**Supplementary Fig.2**).

Figure 2. The associations of accelerometer-derived (AcD) sleep traits (duration, mid-point least active 5-hours (L5), mid-point most active 10-hours (M10), sleep fragmentation, and sleep efficiency) with HbA1c in one-sample Mendelian randomization (MR) in the UK Biobank and in two-sample Mendelian randomization in UK Biobank (UKB) and MAGIC.



1SMR-2SLS: one-sample MR with two-stage least square method.
1SMR-CC-IVW, MR_Egger, LADreg: one-sample Mendelian randomization with collider-correction in inverse-variance weighted, MR-Egger, and LAD regression respectively.
2SMR-UKB/MAGIC-IVW, WM, MR-Egger, MR-Egger_SiMEX: two-sample MR with inverse-variance weighted, weighted median, MR-Egger, MR-Egger with simulation extrapolation SiMEX respectively.
1SD HbA1c in the UK Biobank with accelerometer-derived data is 0.14 log mmol/mol; 1SD HbA1c in the sub-sample of UK Biobank without accelerometer-derived data is 0.15 log mmol/mol; 1SD HbA1c in the MAGIC is 0.41%
Only 1 SNP predicting M10 timing was identified. As such, the 1SMR-CC was not reliable in the simulation process, and the 2SMR-WM/Egger estimates were not available.

Genetic correlations across AcD, SR sleep traits and HbA1c/glucose and multivariable Mendelian randomization

We used cross-trait linkage disequilibrium score (LDSC)[23] regression to determine genetic correlations across all AcD[21] and SR[16,24,25] sleep traits and HbA1c/glucose[22] using GWAS summary statistics (**Figure 3** and **Supplementary Table 5**). Strong genetic correlations were demonstrated between the three sleep timing traits (AcD L5 timing, M10 timing, and SR chronotype; all $R_{LDSC} > 0.8$). There was modest genetic correlation between AcD and SR sleep duration ($R_{LDSC} = 0.43$) and relatively strong genetic correlation between AcD sleep duration and sleep efficiency ($R_{LDSC} = 0.72$). Genetic correlations of SR insomnia with both AcD efficiency and fragmentation were weak (both $R_{LDSC} < 0.18$), with modest correlation between AcD sleep fragmentation and sleep efficiency ($R_{LDSC} = -0.52$). There were weak negative genetic correlations of SR sleep duration with HbA1c and glucose ($R_{LDSC} = -0.07$), and weak positive genetic correlation of insomnia with HbA1c and glucose ($R_{LDSC} \leq 0.1$).

We repeated MR analyses with mutual adjustment using multivariable Mendelian randomization (MVMR)[28] to account for strong correlations between AcD sleep traits (i.e., between L5 and M10, and between AcD sleep duration and efficiency). These results did not differ from the main results, suggesting no independent causal effect of L5, M10, AcD sleep duration or efficiency on HbA1c or glucose (**Supplementary Table 6**).

Figure 3. Heat plot showing linkage disequilibrium score regression genetic correlations across accelerometer-derived (AcD) and self-reported (SR) sleep traits and glycaemic traits.



* p-value < 0.05
** p-value < 0.001
The genetic data of glucose was fasting and was BMI-adjusted

Discussion

In this MR study exploring the potential effects of AcD sleep traits on hyperglycemia, we found no robust evidence that any assessed AcD sleep trait causally affected HbA1c or glucose, including across a suite of sensitivity analyses and in MVMR adjusting for between-trait correlations. Furthermore, consistent MR results of SR sleep traits on HbA1c/glucose conducted in the sub-sample with AcD measurements and those we previously published[15] on a much larger UKB sample, suggested the null effects of AcD sleep trait were unlikely to be explained by selection bias. We showed strong positive genetic correlations between AcD L5 and M10 timing, and SR chronotype, suggesting that AcD and SR measures for sleep timing were capturing the same trait. By contrast, positive correlations between AcD and SR sleep duration were modest and those between SR insomnia and two AcD measures (i.e., low sleep efficiency and high sleep fragmentation) that might be expected to relate to insomnia were weak. Taken together, these findings suggested AcD sleep traits do not causally affect HbA1c or glucose levels, and AcD measures of sleep duration and sleep quality might not simply be 'objective' measures of SR sleep duration and insomnia, but rather captured different underlying sleep characteristics.

Our MR findings did not support the observational associations of AcD sleep measures (e.g., shorter sleep duration,[7] lower sleep efficiency,[8] higher sleep fragmentation[9]) with higher glycaemia levels. These observational relationships might be explained by residual confounding due to socioeconomic position[29] and depression[30], as well as reverse causality as most previous observational studies were cross-sectional. For example, undiagnosed hyperglycaemia might cause nocturia[31] and/or neuropathic pain,[32] which could result in reduced sleep duration and poor sleep quality. Sleep characteristics might be captured differently through assessment of SR and AcD traits. For instance, the SR sleep duration question included naps but this is not the case for AcD sleep duration. The null MR estimates of AcD sleep fragmentation and efficiency (assumed measures of insomnia[6,10]) with HbA1c contrasted with previous MR results suggesting that SR frequent insomnia symptoms results in higher HbA1c levels.[13-15] Several factors could

explain these differences. SR insomnia is by definition experienced, and that experience, rather than the sleep disturbance, might cause or be a proxy for adverse mental or physical health outcomes, such as depression/anxiety,[33] endocrine disorders,[34] and/or appetite changes[35], that influence HbA1c. Besides, sleep can be disturbed in ways not detectable by actigraphy or even polysomnography in some cases. Therefore, AcD sleep fragmentation and efficiency might only reflect insomnia status in terms of sleep changes, but not mental or physical changes. The low genetic correlations of AcD sleep fragmentation (R_{LDSC} = 0.09) and efficiency (R_{LDSC} = -0.18) with SR insomnia supported this idea. It was also possible that genetic contributions to SR and AcD measures of insomnia/sleep quality differed, though heritability estimates using UKB data suggested these were similar (17% for SR insomnia[36] and 22% for AcD fragmentation[21]). Further studies exploring what might contribute to weak/modest correlations between SR and AcD measures of sleep duration and quality/insomnia, are important for correct interpretations and translation into clinical and public health practice of results exploring the health consequences of disturbances of SR and/or AcD sleep traits, though noting that actigraphy data provides limited data about sleep physiology in terms of macro or microstructure.[37]

A key strength of this study was its novelty, being the first, to our knowledge, to use MR to explore potential effects of AcD sleep traits on HbA1c and glucose. We conducted 1SMR, 2SMR, and a range of sensitivity analyses to explore genetic instrument validity. The consistency of findings across these methods, and across samples, increased confidence in our conclusion that AcD sleep traits do not have causal effects on HbA1c or glucose.

A key potential limitation was the possibility that our results could be influenced by selection bias,[38] due to the low recruitment into UKB (5.5% participation[39]), resulting in a cohort that was healthier than the population from which they were drawn,[40] as well as the non-random selection of UKB participants into the AcD sub-sample.[41] Whilst the low participation into UKB could result in selection bias, similar observational and MR associations with a range of outcomes were obtained from the meta-analyses with/without UKB pooled, where these cohorts were with higher response rates (i.e. $\geq$ 70%).[42,43] In this

study, we found participants in the AcD sub-sample were from higher socioeconomic backgrounds, who were less likely to smoke, had lower mean BMI, and had lower levels of prevalent diabetes than those were not in the AcD sub-sample. However, when we compared 1SMR estimates of SR sleep traits on HbA1c/glucose in the AcD sub-sample to the same results in a much larger UKB sample that we previously published, we found similar results,[15] suggesting minimal bias due to selection. It would have been useful to compare prospective multivariable regression associations of AcD sleep traits with HbA1c/glucose to our MR results. However, this was impossible, because AcD sleep traits were obtained, on average, 5 years after the glycaemic traits were measured meaning they could not be used to reflect a causal effect of AcD sleep traits on HbA1c/glucose. Results did not differ in sensitivity analyses that excluded participants with *Eastwood* clarified diabetes[44] and/or baseline HbA1c $\geq$ 48 mmol/mol, suggesting our results are not influenced by having (type 1 or type 2) diabetes or treatment with hypoglycaemics. For all MR analyses, we used genetic variants that passed a p-value threshold of $p < 5 \times 10^{-8}$ in UKB, with limited evidence of replication in an independent cohort.[21] This was because of the dearth of other large studies with genome-wide and AcD sleep data, meaning attempts at replication were limited to pooled results from 3 cohorts (WHITEHALL II Study, COLAUS Study, ROTTERDAM I Study) with 5,819 participants (8% the size of UKB used in the AcD sleep trait GWAS here).[21] Of the 47 SNPs that were genome-wide significant with at least one AcD sleep trait in UKB, 36 were directionally consistent with a p-value threshold > 0.05; 11 were directionally consistent with $p < 0.05$; one was with $p < 0.001$, the multiple testing corrected threshold.[21] Without further replication in larger studies, it was possible that some of the 47 SNPs were false positives and/or had inflated associations with sleep traits. If this was the case then it could result in both our 1SMR and 2SMR results being biased towards the null.[45] However, a recent study[46] from our group has suggested the use of SNPs from GWAS that have not been independently replicated may not result in notable bias. In that MR phenome wide association study of SR insomnia, we used a genetic risk score (GRS) based on genome-wide significant SNPs that had not been replicated and found highly consistent results in sensitivity analyses with two different GRS restricted to replicated SNPs.[46] Participants were predominantly of European ancestry, meaning our

findings may not generalise to other ancestries. Lastly, our study assumed a linear association between AcD sleep traits and HbA1c/glucose. If there was, for example a symmetrical U-shaped association, this linear assumption would bias results toward the null. Despite UKB being the largest study with AcD and genomic data there is limited power to precisely estimate non-linear effects.

Conclusions

We found little evidence to support an effect of any AcD sleep trait on HbA1c or glucose levels across a wide range of MR methods. We cannot rule out non-linear (e.g., U-shaped) effects and acknowledge the need for further GWAS and MR studies of AcD traits in larger samples.

Methods and Materials

The UK Biobank

Between 2006 and 2010, the UKB recruited 503,317 adults (aged 40-69 years) out of 9.2 million invited eligible adults (5.5% response[39]). Information on socio-demographic characteristics and lifestyle including SR sleep traits were obtained using a touchscreen questionnaire at the baseline assessment. Venous blood samples were collected and processed at baseline. In relation to this study, these have been used for measuring HbA1c and glucose levels, and for genotyping. A triaxial accelerometer device (Axivity AX3) was worn continuously for up to 7 days in a sub-sample of participants an average of 5 years after the baseline assessment (range 2.8 to 8.7 years).[21] Funding was available to complete accelerometer data collection on ~100,000, and these participants were invited in batches until 103,711 completed accelerometer assessments.[21] **Figure 1** shows the flowchart of participants from all recruited to

those included in our study. We restricted analyses to those of European ancestry (defined by an in-house k-means cluster analysis performed using R and the first 4 principal components provided by UKB[47]). After applying pre-specified exclusion criteria, we included 73,797 European participants with AcD sleep data in the analyses. Full details of the exclusion criteria and their definitions are presented in **Supplementary Information**.

Accelerometer-derived sleep traits

1) **Accelerometer-derived nocturnal sleep duration** was defined as the summed duration of all nocturnal sleep episodes within the sleep period time windows (SPT-windows). Sleep episodes were defined as any period of at least 5 minutes with no change larger than 5° associated with the z-axis of the accelerometer.[48] The algorithm in GGIR[48] combined all sleep episodes that were not separated by more than 30 minutes and then called that the SPT-window (of which there can only be one per day). Any sleep episodes outside of this window were classified as naps and so didn't count towards the nocturnal sleep duration total. The total duration of all SPT-windows over the activity-monitor wear time was averaged and divided by the number of days (24 hours) to give mean sleep duration per total day. Individuals with an average sleep duration <3 hours or >12 hours were set to missing in this study.

2) **Midpoint least-active 5-hour (L5) timing** was a measure of the midpoint of the least-active (i.e., with minimum average acceleration) 5 hours of each day. The 5-hour periods were defined on a rolling basis (e.g., 1:00 to 6:00, 2:00 to 7:00 and so on). For example, if the midpoint of the least-active 5-hour was 24:00 (0:00) (i.e., a rolling 5-hour was from 21:30 to 2:30) then L5 = 24 (i.e., 24 + 0); if the midpoint of least-active 5-hour was 3:30 then L5 = 27.5 (i.e., 24 + 3.5); and if the midpoint of the least-active 5 hour was 20:30 then L5 = 20.5 (i.e., 24 – 3.5). Thus, a higher L5 score indicated someone was least active in the morning and more likely to have an evening chronotype.

3) **Midpoint most-active 10-hour (M10) timing** was a measure of the midpoint of the most active (i.e., with maximum average acceleration) 10-hour time of day based on a 24-hour clock. It was calculated in a similar way to L5 (see above) except with rolling periods of 10 hours. A higher M10 score indicated someone who was most active in the evening and hence more likely to have an evening chronotype

4) **Nocturnal sleep episode** (defined above) was a measure of sleep fragmentation. Individuals with an average number of sleep episodes ≤5 or ≥30 times were set to missing in this study. We referred to a high number of sleep episodes as 'sleep fragmentation' throughout this paper.

5) **Mean sleep efficiency** was calculated as the nocturnal sleep duration (defined above) divided by the time elapsed between the start of the first inactivity bout and the end of the last inactivity bout (which equals the SPT-window duration) across all valid nights. This was an approximate measure of the proportion of time spent asleep while in bed.

Genetic variants

The genetic variants associated with the 5 AcD sleep traits were obtained from a GWAS conducted in a sub-sample of UKB (n = 85,670, white European), where 44 single nucleotide polymorphisms (SNPs) associated at genome-wide significance ($p < 5 \times 10^{-8}$) with at least one of the 5 AcD traits (11 for sleep duration, 6 for L5 timing, 1 for M10 timing, 21 for sleep fragmentation, and 5 for sleep efficiency).[21] The genetic associations were obtained using a linear mixed model (LMM) adjusting for the effects of population structure, individual relatedness, age at accelerometer assessment, sex, study centre, season of accelerometer wear, and genotype array (**Supplementary Information**).[21] **Supplementary Table 1** provides the list of SNPs used as instrumental variables for each of the AcD sleep traits. The number of SNPs used for each AcD sleep trait, the mean F-statistic, and R^2 across all SNPs, as well as the unweighted allele score, for each exposure are provided in **Supplementary Table 2**.

HbA1c and glucose measurement

At the UKB baseline visit, venous blood samples were taken. HbA1c was measured in red blood cells by HPLC on a Bio-Rad VARIANT II Turbo analyzer and glucose was assayed in serum by hexokinase analysis on a Beckman Coulter AU5800.[49] Samples were assumed to be non-fasting, because participants were not advised to fast before attending. They were asked to record the last time they ate or drank anything other than water before attending the clinic and those answers were used to derive 'fasting time' prior to sampling, which we controlled for in analyses. During routine quality control checks, the UKB laboratory team observed that, due to a sample processing error, ~ 8% of the glucose assay results were lower than expected and therefore a 'dilution correction factor' was provided and applied to these results.[50] The HbA1c samples were not affected. We used HbA1c as our primary outcome because it provides a stable measure over a period of ~4 weeks and is therefore less prone to regression dilution bias and is more statistically efficient compared with non-fasting glucose which we explored as a secondary outcome.

Sex-combined meta-analysis summary statistics of genetic variants related to HbA1c (%, n= ~149,054, mean age 59.7 years, 57.9% female)) and BMI adjusted fasting glucose (mmol/l, n= ~ 196,575, mean age 50.9 years, 51.2% female)) were also obtained from the MAGIC consortium.[22] Participants were of European descent without diagnosed diabetes. Glucose was measured after fasting and BMI adjusted in the MAGIC related analyses (e.g., 2SMR-MAGIC).

Statistical analyses

UKB HbA1c/glucose data were right skewed and the units (HbA1c: in mmol/mol and non-fasting glucose: in mmol/l) differed to those obtained from MAGIC[22] (HbA1c: in % and fasting glucose with BMI

adjusted: in mmol/l). Therefore, we natural log-transformed the HbA1c/glucose levels in UKB and then converted them into SD units (HbA1c: 1 SD = 0.14 log mmol/mol; non-fasting glucose: 1SD = 0.16 log mmol/l), as well as those from MAGIC[22] (HbA1c: 1SD = 0.41%; fasting-glucose: 1SD = 0.84 mmol/l). As such, we estimated the difference in mean HbA1c/glucose in SD units per unit increase in each AcD sleep trait in all MR analyses. We repeated all MR analyses taking glucose as the outcome.

Main analyses assessing the effects of AcD sleep traits on HbA1c and glucose

One-sample Mendelian randomization

We generated unweighted allele scores[51] for the AcD sleep traits as the total number of adverse sleep trait increasing alleles present identified in the relevant GWAS[21] for each participant. Two-stage least squares (2SLS) instrumental variable analyses were performed to obtain the MR estimate of each trait on HbA1c and glucose. We adjusted for assessment centre and 40 genetic principal components to minimize confounding by population stratification,[52] as well as baseline age, sex, genotyping chip, fasting time and dilution factor (for glucose only) to reduce random variation in these analyses.

Two-sample Mendelian randomization

We used summary associations between the genetic instruments and AcD sleep traits identified in the GWAS[21] for Sample 1 (the SNP-exposure association summary results). For sample 2 (the SNP-outcome association summary results), we used two independent samples: **Sample 2-UKB**: estimates of the associations between the genetic instruments and HbA1c/glucose were from the sample of the UKB participants who did not participate in the accelerometer GWAS[21] (HbA1c: n = ~292,000 and glucose: n = ~267,000). The SNP – outcome associations were obtained via the multivariable adjusted linear model

accounting for assessment centre and 40 genetic principal components, baseline age, sex, and genotyping chip, fasting time and dilution factor (for glucose only); **Sample 2-MAGIC**: the summary statistics were from the MAGIC consortium.[22] We conducted inverse-variance weighted (IVW) regression of the Wald ratio for each SNP under a multiplicative random-effects model[53] to obtain the causal estimates using the "*TwoSampleMR*" package in R (version 0.4.26).[54] Further details were presented in the **Supplementary Information**.

1SMR and 2SMR analyses taking SR sleep traits (sleep duration, chronotype, insomnia symptoms)[16,24,25] as the exposures were conducted for comparison. The detailed information of the SR sleep traits and their genetic information were presented in the **Supplementary Information**.

Sensitivity and additional analyses

Accounting for the impact of diabetes in the MR analyses

To account for the potential impact of either diabetes or the treatment for diabetes on glycaemic levels, we repeated the analyses with UKB participants (1SMR and 2SMR-UKB) excluding those with diabetes defined by the *Eastwood* algorithm (probable/possible type 1 diabetes and type 2 diabetes)[44] and/or additionally those with a baseline HbA1c ≥ 48 mmol/mol (≥ 6.5%, the threshold for diagnosing diabetes). We referred to those with *Eastwood* clarified diabetes and/or baseline HbA1c ≥ 48 mmol/mol as "*participants with diabetes*".

Assessing Mendelian randomization assumptions and evaluating bias

MR analysis requires three key assumptions to be satisfied in order to obtain valid causal estimates.[55] First, the genetic instrument should be robustly associated with the exposure (instrument strength). We

investigated this using first-stage F-statistic and R^2 values in both 1SMR and 2SMR. Further details were presented in the **Supplementary Information.** Second, there should be no confounding between the genetic instrument and the outcome. In MR, this can occur as a result of population stratification. We have attempted to minimise this by restricting analyses to those of European ancestry and adjusted for genetic principal components and assessment centre.[52] Third, the genetic instrument should influence the outcome exclusively through its effect on the exposure. This would be violated by unbalanced horizontal pleiotropy. We have undertaken the following sensitivity analyses to explore potential bias due to horizontal pleiotropy.

In 1SMR, we explored between SNP heterogeneity via the *Sargan* over-identification test.[56] Between SNP heterogeneity may be due to horizontal pleiotropy. Additionally, we applied the recently proposed Collider-Correction[27] method to implement three further pleiotropy sensitivity analyses commonly used in 2SMR (i.e., IVW, MR-Egger, and least absolute deviation regression (LADreg) being similar to the weighted median (WM) approach). Collider-Correction was needed in 1SMR to account jointly for pleiotropy and weak instruments bias.[26] Further details were presented in **Supplementary Information**. We subsequently referred to this as 1SMR with Collider-Correction as 1SMR-CC. In 2SMR, we assessed between SNP heterogeneity using the Cohan Q statistic. We then explored unbalanced horizontal pleiotropy by comparing the results of the IVW regression with standard pleiotropy-robust MR methods: WM and MR-Egger, referred to as 2SMR-UKB/MAGIC WM and 2SMR-UKB/MAGIC MR-Egger. To account for weak instrument bias (i.e., towards the null) in the 2SMR MR-Egger estimates, we used simulation extrapolation SiMEX.[57] We referred it as 2SMR-UKB/MAGIC MR-Egger_SiMEX.

Exploring selection bias due to non-random selection into the sub-sample with AcD data.

We compared distributions of HbA1c, glucose, diabetes prevalence, BMI, and a range of socioeconomic and behavioral characteristics (**Supplementary Information**) between those included in the sub-sample

of UKB with AcD data (n = 73,797) and those not in this sample (n = 306,317), as well as the whole available UKB sample (n = 385,163), because the AcD sub-sample were recruited non-randomly. In addition, we compared the 1SMR estimates of SR sleep traits (sleep duration, chronotype, insomnia symptoms) on HbA1c/glucose in this study (n = 73,797) with those 1SMR estimates, previously published in nearly all UKB participants[9] (n = 336,999, after limiting to White British ancestry and with complete data on genetics, SR sleep traits and HbA1c). Similar estimates between the 1SMR estimates for these SR traits in the much larger sample and the selected AcD sub-sample would suggest limited selection bias in the AcD sub-sample analyses presented here.

Genetic correlation between sleep traits

We used LDSC[23] (**Supplementary Information**), as an additional analysis, to aid the interpretation of the MR AcD results and interpret any differences that might be observed between our AcD data generated and our previously reported MR effects of SR sleep traits on HbA1c/glucose.[15] We assessed genetic correlations between all AcD and SR sleep traits. For completeness, we also explored genetic correlations of each AcD and SR traits with HbA1c and glucose (fasting and BMI adjusted). LDSC uses data from across genome. The full summary statistics of all sleep traits were obtained from the Sleep Disorder Knowledge Portal https://sleep.hugeamp.org/. Those for HbA1c and glucose were from the MAGIC consortium.[22]

Whenever we observed strong genetic correlation between any two AcD sleep traits (i.e., ≥ 0.7), we undertook MVMR[28] to explore whether we could determine individual AcD sleep trait direct effect (**Supplementary Information**).

Data availability

All UK Biobank data are available to the research community via an application, with full details of this process provided on the study website (https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access). Summary data on sleep traits and glycaemic traits are available unrestricted and can be downloaded, as we have for this study from the Sleep Disorder Knowledge Portal https://sleep.hugeamp.org/ and the MAGIC from www.magicinvestigators.org respectively.

R scripts for the key analyses are available on GitHub at: https://github.com/jamesliu0501/Accelerometer-derived-sleep-traits-on-HbA1c-MR-project-.git. For statistical code relating to the individual level data analysis in UK Biobank, please contact the corresponding author via ieu_james.liu@bristol.ac.uk.

J.L, R.C.R, and D.A.L are the guarantors of this work and had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

References

1 Shan, Z., Ma, H., Xie, M., Yan, P., Guo, Y., Bao, W. *et al.* Sleep duration and risk of type 2 diabetes: a meta-analysis of prospective studies. *Diabetes Care* **38**, 529-537, doi:10.2337/dc14-2073 (2015).

2 Green, M. J., Espie, C. A., Popham, F., Robertson, T. & Benzeval, M. Insomnia symptoms as a cause of type 2 diabetes Incidence: a 20 year cohort study. *BMC Psychiatry* **17**, 94, doi:10.1186/s12888-017-1268-4 (2017).

3 Vetter, C., Devore, E. E., Ramin, C. A., Speizer, F. E., Willett, W. C. & Schernhammer, E. S. Mismatch of Sleep and Work Timing and Risk of Type 2 Diabetes. *Diabetes Care* **38**, 1707-1713, doi:10.2337/dc15-0302 (2015).

4 Rutters, F., Besson, H., Walker, M., Mari, A., Konrad, T., Nilsson, P. M. *et al.* The Association Between Sleep Duration, Insulin Sensitivity, and β-Cell Function: The EGIR-RISC Study. *The Journal of Clinical Endocrinology & Metabolism* **101**, 3272-3280, doi:10.1210/jc.2016-1045 (2016).

5 Deng, H. B., Tam, T., Zee, B. C., Chung, R. Y., Su, X., Jin, L. *et al.* Short Sleep Duration Increases Metabolic Impact in Healthy Adults: A Population-Based Cohort Study. *Sleep* **40**, doi:10.1093/sleep/zsx130 (2017).

6 Reed, D. L. & Sacco, W. P. Measuring Sleep Efficiency: What Should the Denominator Be? *J Clin Sleep Med* **12**, 263-266, doi:10.5664/jcsm.5498 (2016).

7 Brouwer, A., van Raalte, D. H., Rutters, F., Elders, P. J. M., Snoek, F. J., Beekman, A. T. F. *et al.* Sleep and HbA(1c) in Patients With Type 2 Diabetes: Which Sleep Characteristics Matter Most? *Diabetes Care* **43**, 235-243, doi:10.2337/dc19-0550 (2020).

8 Whitaker, K. M., Lutsey, P. L., Ogilvie, R. P., Pankow, J. S., Bertoni, A., Michos, E. D. *et al.* Associations between polysomnography and actigraphy-based sleep indices and glycemic control among those with and without type 2 diabetes: the Multi-Ethnic Study of Atherosclerosis. *Sleep* **41**, doi:10.1093/sleep/zsy172 (2018).

9 Yano, Y., Gao, Y., Johnson, D. A., Carnethon, M., Correa, A., Mittleman, M. A. *et al.* Sleep Characteristics and Measures of Glucose Metabolism in Blacks: The Jackson Heart Study. *J Am Heart Assoc* **9**, e013209, doi:doi:10.1161/JAHA.119.013209 (2020).

10 Hermans, L. W. A., Regis, M., Fonseca, P., Hoondert, B., Leufkens, T. R. M., Overeem, S. *et al.* Sleep-Wake Survival Dynamics in People with Insomnia. *Nat Sci Sleep* **13**, 349-360, doi:10.2147/nss.S295699 (2021).

11 Fritz, J., Phillips, A. J. K., Hunt, L. C., Imam, A., Reid, K. J., Perreira, K. M. *et al.* Cross-sectional and prospective associations between sleep regularity and metabolic health in the Hispanic Community Health Study/Study of Latinos. *Sleep* **44**, doi:10.1093/sleep/zsaa218 (2020).

12 Sondrup, N., Termannsen, A.-D., Eriksen, J. N., Hjorth, M. F., Færch, K., Klingenberg, L. *et al.* Effects of sleep manipulation on markers of insulin sensitivity: A systematic review and meta-analysis of randomized controlled trials. *Sleep Medicine Reviews* **62**, 101594, doi:https://doi.org/10.1016/j.smrv.2022.101594 (2022).

13 Reynolds, A. C., Dorrian, J., Liu, P. Y., Van Dongen, H. P. A., Wittert, G. A., Harmer, L. J. *et al.* Impact of Five Nights of Sleep Restriction on Glucose Metabolism, Leptin and Testosterone in Young Adult Men. *PLOS ONE* **7**, e41218, doi:10.1371/journal.pone.0041218 (2012).

14 Lawlor, D. A., Harbord, R. M., Sterne, J. A., Timpson, N. & Davey Smith, G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. *Statistics in medicine* **27**, 1133-1163, doi:10.1002/sim.3034 (2008).

15 Liu, J., Richmond, R. C., Bowden, J., Barry, C., Dashti, H. S., Daghlas, I. *et al.* Assessing the Causal Role of Sleep Traits on Glycated Hemoglobin: A Mendelian Randomization Study. *Diabetes Care* **45**, 772-781, doi:10.2337/dc21-0089 (2022).
16 Jansen, P. R., Watanabe, K., Stringer, S., Skene, N., Bryois, J., Hammerschlag, A. R. *et al.* Genome-wide analysis of insomnia in 1,331,010 individuals identifies new risk loci and functional pathways. *Nat Genet* **51**, 394-403, doi:10.1038/s41588-018-0333-3 (2019).
17 Yuan, S. & Larsson, S. C. An atlas on risk factors for type 2 diabetes: a wide-angled Mendelian randomisation study. *Diabetologia*, doi:10.1007/s00125-020-05253-x (2020).
18 Wang, J., Kwok, M. K., Au Yeung, S. L., Li, A. M., Lam, H. S., Leung, J. Y. Y. *et al.* Sleep duration and risk of diabetes: Observational and Mendelian randomization studies. *Prev Med* **119**, 24-30, doi:10.1016/j.ypmed.2018.11.019 (2019).
19 Bos, M. M., van Heemst, D., Donga, E., de Mutsert, R., Rosendaal, F. R., Blauw, G. J. *et al.* The Association between Habitual Sleep Duration and Sleep Quality with Glycemic Traits: Assessment by Cross-Sectional and Mendelian Randomization Analyses. *J Clin Med* **8**, 682, doi:10.3390/jcm8050682 (2019).
20 Doherty, A., Smith-Byrne, K., Ferreira, T., Holmes, M. V., Holmes, C., Pulit, S. L. *et al.* GWAS identifies 14 loci for device-measured physical activity and sleep duration. *Nature Communications* **9**, 5257, doi:10.1038/s41467-018-07743-4 (2018).
21 Jones, S. E., van Hees, V. T., Mazzotti, D. R., Marques-Vidal, P., Sabia, S., van der Spek, A. *et al.* Genetic studies of accelerometer-based sleep measures yield new insights into human sleep behaviour. *Nat Commun* **10**, 1585, doi:10.1038/s41467-019-09576-1 (2019).
22 Chen, J., Spracklen, C. N., Marenne, G., Varshney, A., Corbin, L. J., Luan, J. *et al.* The trans-ancestral genomic architecture of glycemic traits. *Nat Genet* **53**, 840-860, doi:10.1038/s41588-021-00852-9 (2021).
23 Bulik-Sullivan, B., Finucane, H. K., Anttila, V., Gusev, A., Day, F. R., Loh, P.-R. *et al.* An atlas of genetic correlations across human diseases and traits. *Nature Genetics* **47**, 1236-1241, doi:10.1038/ng.3406 (2015).
24 Dashti, H. S., Jones, S. E., Wood, A. R., Lane, J. M., van Hees, V. T., Wang, H. *et al.* Genome-wide association study identifies genetic loci for self-reported habitual sleep duration supported by accelerometer-derived estimates. *Nat Commun* **10**, 1100, doi:10.1038/s41467-019-08917-4 (2019).
25 Jones, S. E., Lane, J. M., Wood, A. R., van Hees, V. T., Tyrrell, J., Beaumont, R. N. *et al.* Genome-wide association analyses of chronotype in 697,828 individuals provides insights into circadian rhythms. *Nat Commun* **10**, 343, doi:10.1038/s41467-018-08259-7 (2019).
26 Burgess, S. & Thompson, S. G. Avoiding bias from weak instruments in Mendelian randomization studies. *Int J Epidemiol* **40**, 755-764, doi:10.1093/ije/dyr036 (2011).
27 Barry, C., Liu, J., Richmond, R., Rutter, M. K., Lawlor, D. A., Dudbridge, F. *et al.* Exploiting collider bias to apply two-sample summary data Mendelian randomization methods to one-sample individual level data. *PLOS Genetics* **17**, e1009703, doi:10.1371/journal.pgen.1009703 (2021).
28 Sanderson, E., Davey Smith, G., Windmeijer, F. & Bowden, J. An examination of multivariable Mendelian randomization in the single-sample and two-sample summary data settings. *International Journal of Epidemiology* **48**, 713-727, doi:10.1093/ije/dyy262 (2018).

29 Xiao, Q. & Hale, L. Neighborhood socioeconomic status, sleep duration, and napping in middle-to-old aged US men and women. *Sleep* **41**, doi:10.1093/sleep/zsy076 (2018).
30 Stamatakis, K. A. & Punjabi, N. M. Long sleep duration: a risk to health or a marker of risk? *Sleep medicine reviews* **11**, 337-339, doi:10.1016/j.smrv.2007.07.006 (2007).
31 Ancoli-Israel, S., Bliwise, D. L. & Nørgaard, J. P. The effect of nocturia on sleep. *Sleep medicine reviews* **15**, 91-97, doi:10.1016/j.smrv.2010.03.002 (2011).
32 Farhadi, A., Vosough, M., Zhang, J.-S., Tahamtani, Y. & Shahpasand, K. A Possible Neurodegeneration Mechanism Triggered by Diabetes. *Trends in Endocrinology & Metabolism* **30**, 692-700, doi:10.1016/j.tem.2019.07.012 (2019).
33 Lind, M. J. & Gehrman, P. R. Genetic Pathways to Insomnia. *Brain Sci* **6**, 64, doi:10.3390/brainsci6040064 (2016).
34 Van Cauter, E., Spiegel, K., Tasali, E. & Leproult, R. Metabolic consequences of sleep and sleep loss. *Sleep Med* **9 Suppl 1**, S23-28, doi:10.1016/s1389-9457(08)70013-3 (2008).
35 Greer, S. M., Goldstein, A. N. & Walker, M. P. The impact of sleep deprivation on food desire in the human brain. *Nat Commun* **4**, 2259, doi:10.1038/ncomms3259 (2013).
36 Lane, J. M., Jones, S. E., Dashti, H. S., Wood, A. R., Aragam, K. G., van Hees, V. T. *et al.* Biological and clinical insights from genetics of insomnia symptoms. *Nat Genet* **51**, 387-393, doi:10.1038/s41588-019-0361-7 (2019).
37 Smith, M. T., McCrae, C. S., Cheung, J., Martin, J. L., Harrod, C. G., Heald, J. L. *et al.* Use of Actigraphy for the Evaluation of Sleep Disorders and Circadian Rhythm Sleep-Wake Disorders: An American Academy of Sleep Medicine Systematic Review, Meta-Analysis, and GRADE Assessment. *J Clin Sleep Med* **14**, 1209-1230, doi:10.5664/jcsm.7228 (2018).
38 Munafò, M. R., Tilling, K., Taylor, A. E., Evans, D. M. & Davey Smith, G. Collider scope: when selection bias can substantially influence observed associations. *International Journal of Epidemiology* **47**, 226-235, doi:10.1093/ije/dyx206 (2017).
39 Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J. *et al.* UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med* **12**, e1001779, doi:10.1371/journal.pmed.1001779 (2015).
40 Keyes, K. M. & Westreich, D. UK Biobank, big data, and the consequences of non-representativeness. *The Lancet* **393**, 1297, doi:10.1016/S0140-6736(18)33067-8 (2019).
41 Tyrrell, J., Zheng, J., Beaumont, R., Hinton, K., Richardson, T. G., Wood, A. R. *et al.* Genetic predictors of participation in optional components of UK Biobank. *Nature Communications* **12**, 886, doi:10.1038/s41467-021-21073-y (2021).
42 Gregson, J., Kaptoge, S., Bolton, T., Pennells, L., Willeit, P., Burgess, S. *et al.* Cardiovascular Risk Factors Associated With Venous Thromboembolism. *JAMA Cardiol* **4**, 163-173, doi:10.1001/jamacardio.2018.4537 (2019).
43 Warrington, N. M., Beaumont, R. N., Horikoshi, M., Day, F. R., Helgeland, Ø., Laurin, C. *et al.* Maternal and fetal genetic effects on birth weight and their relevance to cardio-metabolic risk factors. *Nat Genet* **51**, 804-814, doi:10.1038/s41588-019-0403-1 (2019).
44 Eastwood, S. V., Mathur, R., Atkinson, M., Brophy, S., Sudlow, C., Flaig, R. *et al.* Algorithms for the Capture and Adjudication of Prevalent and Incident Diabetes in UK Biobank. *PLoS One* **11**, e0162388, doi:10.1371/journal.pone.0162388 (2016).

45 Taylor, A. E., Davies, N. M., Ware, J. J., VanderWeele, T., Smith, G. D. & Munafò, M. R. Mendelian randomization in health research: using appropriate genetic variants and avoiding biased estimates. *Econ Hum Biol* **13**, 99-106, doi:10.1016/j.ehb.2013.12.002 (2014).
46 Gibson, M. J., Lawlor, D. A. & Millard, L. A. C. Identifying the potential role of insomnia on multimorbidity: A Mendelian randomization phenome-wide association study in UK Biobank. *medRxiv*, 2022.2001.2011.22269005, doi:10.1101/2022.01.11.22269005 (2022).
47 Ruth E Mitchell, G. H., Tom Dudding, Laura Corbin, Sean Harrison, Lavinia Paternoster. UK Biobank Genetic Data: MRC-IEU Quality Control, version 2, 18/01/2019. (MRC Integrative Epidemiology Unit (IEU), University of Bristol, UK, 2019).
48 van Hees, V. T., Sabia, S., Jones, S. E., Wood, A. R., Anderson, K. N., Kivimäki, M. *et al.* Estimating sleep parameters using an accelerometer without sleep diary. *Sci Rep* **8**, 12975, doi:10.1038/s41598-018-31266-z (2018).
49 UKBiobank. *UK Biobank Biomarker Panel*, <https://www.ukbiobank.ac.uk/wp-content/uploads/2013/11/BCM023_ukb_biomarker_panel_website_v1.0-Aug-2015.pdf> (2015).
50 Allen, N. E., Arnold, M., Parish, S., Hill, M., Sheard, S., Callen, H. *et al.* Approaches to minimising the epidemiological impact of sources of systematic and random variation that may affect biochemistry assay data in UK Biobank. *Wellcome Open Res* **5**, 222, doi:10.12688/wellcomeopenres.16171.2 (2020).
51 Burgess, S. & Thompson, S. G. Use of allele scores as instrumental variables for Mendelian randomization. *International Journal of Epidemiology* **42**, 1134-1144, doi:10.1093/ije/dyt093 (2013).
52 Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L. T., Sharp, K. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* **562**, 203-209, doi:10.1038/s41586-018-0579-z (2018).
53 Burgess, S. B., Jack. Integrating summarized data from multiple genetic variants in Mendelian randomization: bias and coverage properties of inverse-variance weighted methods. (2015).
54 Hemani, G., Zheng, J., Elsworth, B., Wade, K. H., Haberland, V., Baird, D. *et al.* The MR-Base platform supports systematic causal inference across the human phenome. *eLife* **7**, e34408, doi:10.7554/eLife.34408 (2018).
55 Davies, N. M., Holmes, M. V. & Davey Smith, G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. *BMJ* **362**, k601, doi:10.1136/bmj.k601 (2018).
56 Baum, C. F., Schaffer, M. E. & Stillman, S. Instrumental Variables and GMM: Estimation and Testing. *The Stata Journal* **3**, 1-31, doi:10.1177/1536867X0300300101 (2003).
57 Bowden, J., Del Greco, M. F., Minelli, C., Davey Smith, G., Sheehan, N. A. & Thompson, J. R. Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I2 statistic. *Int J Epidemiol* **45**, 1961-1974, doi:10.1093/ije/dyw220 (2016).

Acknowledgements

This research has been conducted using the UK Biobank Resource under application 6818. We would like to thank the participants and researchers from the UK Biobank who contributed or collected data. Data on glycaemic traits have been contributed by MAGIC investigators and have been downloaded from www.magicinvestigators.org. We thank Dr. Eleanor Sanderson (MRC/IEU, University of Bristol) for providing statistical support on multivariable Mendelian randomization.

Author contributions

J.L. affirms that this manuscript is an honest, accurate, and transparent account of the study being reported, that no important aspects of the study have been omitted, and that any discrepancies from the study as planned (and, if relevant, registered) have been explained. J.L. carried out the data analysis. M.K.R. and D.A.L. conceived the idea for the study. M.K.R., R.A.E., D.W.R., S.G.A., M.J.C., M.N.W., T.M.F., A.R.W., J.B., and D.A.L. obtained funds for the project. D.A.L. and M.K.R. designed the study. J.L. carried out the data analysis. J.L., R.C.R., E.L.A., D.A.L., M.K.R., and J.B. wrote the initial draft, with subsequent input from other authors. All authors made critical revisions to the paper. J.L., R.C.R., E.L.A., D.A.L., and M.K.R. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Competing interests

M.K.R. reports modest owning of shares in GlaxoSmithKline unrelated to this work. J.B reports receiving consultancy fees from Novartis unrelated to this work. D.A.L has received support from Roche Diagnostics and Medtronic Ltd for research unrelated to that presented here. No other potential conflicts of interest relevant to this article were reported.

Funding

This work is supported by a Diabetes UK grant (17/0005700), which funds J.L, A.K.W, and S.E.J's salary. J.L, R.C.R, E.L.A, and D.A.L work in a unit that is funded by the University of Bristol and the UK Medical Research Council (MC_UU_00011/1 and MC_UU_00011/6) and D.A.L's contribution to this paper was supported by a grant from the British Heart Foundation (AA/18/1/34219) an NIHR Senior Investigator (NF-0616-10102) and BHF Chair in Cardiovascular Science and Clinical Epidemiology (CH/F/20/90003). R.C.R is a de Pass Vice Chancellor's research fellow at the University of Bristol. H.S.D. is funded by the National Institutes of Health (K99HL153795). R.S is funded by the National Institute of Health (R01DK107859 and R01DK105072). R.S is awarded the Phyllis and Jerome Lyle Rappaport Massachusetts General Hospital Research Scholar Award. J.B is funded by an Establishing Excellence in England (E^3) grant awarded to the University of Exeter. D.W.R is funded by MRC programme grant (MR/P023576/1), and is a Wellcome Investigator, Wellcome Trust (107849/Z/15/Z and 107849/A/15/Z). C.S.B is supported by the Wellcome Trust via a Ph.D. (218495/Z/19/Z). S.D.K is supported by the NIHR Oxford Biomedical Research Centre. E.L.A is funded by a UKRI Future Leaders Fellowship (MR/W011581/1).

These funders did not have any role in the study design, analyses or interpretation of results. The views expressed in the paper are those of the authors and not necessarily any acknowledged funders.

Ethical approval

The UKB has received ethical approval from the U.K. National Health Service National Research Ethics Service (London, U.K.) (ref 11/NW/0382).

Figure Legends

Figure 1 Flowchart of the participants included in the main analyses of effects of accelerometer-derived sleep traits on HbA1c in the UK Biobank.

Figure 2 The associations of accelerometer-derived (AcD) sleep traits (duration, mid-point least active 5-hours (L5), mid-point most active 10-hours (M10), sleep fragmentation, and sleep efficiency) with HbA1c in one-sample Mendelian randomization in the UK Biobank and in two-sample Mendelian randomization in UK Biobank (UKB) and MAGIC.

Figure 3 Heat plot showing linkage disequilibrium score regression genetic correlations across accelerometer-derived and self-reported sleep traits and glycaemic traits.

Supplementary Figure 1 The associations of accelerometer-derived (AcD) sleep duration, mid-point least active 5-hours (L5), mid-point most active 10-hours (M10), sleep fragmentation, and sleep efficiency with glucose in one-sample Mendelian randomization in the UK Biobank and in two-sample Mendelian randomization in UK Biobank (UKB) and MAGIC.

Supplementary Figure 2 The one-sample Mendelian randomization estimates of self-reported (SR) sleep traits with: a) HbA1c and b) non-fasting glucose in European UKB participants with accelerometer-derived sleep data, and in all available White British UKB participants.


UK Biobank recruited participants
N = 503,317
Successfully genotyped participants in European ancestry
N = 464,711 (92.3%)
Removed due to failing UKB genetic data MRC-IEU quality control*
N= 79,460
• Sex mismatch (n = 366)
• Sex chromosome aneuploidy (n = 626)
• Outliers in heterozygosity and missing rates (n = 881)
• High relatedness (n = 8)
• Minimal relatedness (n = 77,866)
Withdrew consent by 22 Feb 2022 (n = 88)
Available participants with self-reported sleep data
N = 385,163 (76.5%)
Sensitivity analysis sample (excluding individuals with diabetes†)
N = 347,299 (69.0%))
Removed due to failing activity-monitor data quality control
N= 5,049
• Data problem (n = 2,867)
• Suboptimal wear time (n = 1,834)
• Suboptimal calibration (n = 4)
• Unable to calibrate activity data (n = 183)
Outliers (> 3rd quartile + 1.5 * IQR):
• Data recording error (n = 851)
• Interrupted recording periods (n = 1,652)
• Duration interrupted recording periods (n = 1,652)
Available participants with accelerometer-derived sleep data
N =78,846 (15.7%)
Main analysis
N =73,797 (14.7%)
Sensitivity analysis sample (excluding individuals with diabetes†)
N =67,530 (13.4%)


Associations of AcD sleep duration with HbA1c
Methods
Estimates
1SMR-2SLS
-0.11 (-0.22 to 0.01)
1SMR-CC-IVW
-0.07 (-0.17 to 0.03)
1SMR-CC-MR_Egger
0.14 (-0.12 to 0.39)
1SMR-CC-LADreg
0.01 (-0.14 to 0.16)
2SMR-UKB-IVW
-0.02 (-0.11 to 0.07)
2SMR-UKB-WM
0.00 (-0.09 to 0.08)
2SMR-UKB-MR_Egger
-0.16 (-0.38 to 0.06)
2SMR-UKB-MR_Egger_SiMEX
-0.18 (-0.42 to 0.07)
2SMR-MAGIC-IVW
-0.09 (-0.20 to 0.03)
2SMR-MAGIC-WM
-0.09 (-0.20 to 0.02)
2SMR-MAGIC-MR_Egger
-0.10 (-0.43 to 0.24)
2SMR-MAGIC-MR_Egger_SiMEX
-0.17 (-0.49 to 0.16)
-0.5 -0.4 -0.3 -0.2 -0.1 0 0.1 0.2 0.3 0.4
SD increment per hr increase
Associations of L5 timing with HbA1c
Methods
Estimates
1SMR-2SLS
0.01 (-0.12 to 0.14)
1SMR-CC-IVW
0.01 (-0.07 to 0.09)
1SMR-CC-MR_Egger
0.00 (-0.18 to 0.19)
1SMR-CC-LADreg
-0.02 (-0.15 to 0.11)
2SMR-UKB-IVW
0.03 (-0.03 to 0.09)
2SMR-UKB-WM
0.07 (0.00 to 0.13)
2SMR-UKB-MR_Egger
0.05 (-0.06 to 0.16)
2SMR-UKB-MR_Egger_SiMEX
0.05 (-0.06 to 0.17)
2SMR-MAGIC-IVW
0.05 (-0.06 to 0.17)
2SMR-MAGIC-WM
0.02 (-0.07 to 0.12)
2SMR-MAGIC-MR_Egger
0.01 (-0.22 to 0.23)
2SMR-MAGIC-MR_Egger_SiMEX
0.00 (-0.19 to 0.20)
-0.225 -0.15 -0.1 -0.05 0 0.05 0.1 0.15 0.2
SD increment per hr increase
Associations of M10 timing with HbA1c
Methods
Estimates
1SMR-2SLS
-0.24 (-0.52 to 0.05)
1SMR-CC-IVW
NA (NA to NA)
1SMR-CC-MR_Egger
NA (NA to NA)
1SMR-CC-LADreg
NA (NA to NA)
2SMR-UKB-IVW
-0.02 (-0.19 to 0.16)
2SMR-UKB-WM
NA (NA to NA)
2SMR-UKB-MR_Egger
NA (NA to NA)
2SMR-UKB-MR_Egger_SiMEX
NA (NA to NA)
2SMR-MAGIC-IVW
0.05 (-0.18 to 0.28)
2SMR-MAGIC-WM
NA (NA to NA)
2SMR-MAGIC-MR_Egger
NA (NA to NA)
2SMR-MAGIC-MR_Egger_SiMEX
NA (NA to NA)
-0.5 0 0.5
SD increment per hr increase
Associations of sleep fragmentation with hba1c
Methods
Estimates
1SMR-2SLS
-0.01 (-0.03 to 0.01)
1SMR-CC-IVW
-0.01 (-0.04 to 0.02)
1SMR-CC-MR_Egger
0.00 (-0.21 to 0.21)
1SMR-CC-LADreg
-0.06 (-0.10 to -0.01)
2SMR-UKB-IVW
-0.01 (-0.03 to 0.02)
2SMR-UKB-WM
-0.01 (-0.03 to 0.00)
2SMR-UKB-MR_Egger
0.02 (-0.10 to 0.14)
2SMR-UKB-MR_Egger_SiMEX
0.03 (-0.13 to 0.20)
2SMR-MAGIC-IVW
0.00 (-0.01 to 0.02)
2SMR-MAGIC-WM
0.00 (-0.01 to 0.02)
2SMR-MAGIC-MR_Egger
0.02 (-0.06 to 0.10)
2SMR-MAGIC-MR_Egger_SiMEX
0.03 (-0.08 to 0.13)
-0.2 -0.15 -0.1 -0.05 0 0.05 0.1 0.15 0.2
SD increment per fragmentation (times) increase
Associations of sleep efficiency with HbA1c
Methods
Estimates
1SMR-2SLS
0.00 (-0.02 to 0.03)
1SMR-CC-IVW
0.00 (-0.02 to 0.03)
1SMR-CC-MR_Egger
0.00 (-0.05 to 0.06)
1SMR-CC-LADreg
0.01 (-0.03 to 0.05)
2SMR-UKB-IVW
0.00 (-0.01 to 0.01)
2SMR-UKB-WM
0.00 (-0.01 to 0.02)
2SMR-UKB-MR_Egger
-0.02 (-0.04 to 0.00)
2SMR-UKB-MR_Egger_SiMEX
-0.02 (-0.04 to 0.00)
2SMR-MAGIC-IVW
0.00 (-0.02 to 0.02)
2SMR-MAGIC-WM
-0.01 (-0.02 to 0.01)
2SMR-MAGIC-MR_Egger
-0.02 (-0.06 to 0.03)
2SMR-MAGIC-MR_Egger_SiMEX
-0.02 (-0.07 to 0.03)
-0.075 -0.05 -0.025 0 0.025 0.05 0.075
SD increment per % increase

The LDSC estimated genetic correlations




Associations of AcD sleep duration with glucose
Methods
Estimates
1SMR-2SLS
0.09 (-0.04 to 0.22)
1SMR-CC-IVW
0.09 (-0.01 to 0.20)
1SMR-CC-MR_Egger
0.09 (-0.20 to 0.38)
1SMR-CC-LADreg
0.08 (-0.15 to 0.30)
2SMR-UKB-IVW
0.01 (-0.06 to 0.09)
2SMR-UKB-WM
0.00 (-0.08 to 0.08)
2SMR-UKB-MR_Egger
-0.18 (-0.34 to -0.02)
2SMR-UKB-MR_Egger_SiMEX
-0.19 (-0.37 to -0.01)
2SMR-MAGIC-IVW
-0.05 (-0.12 to 0.02)
2SMR-MAGIC-WM
-0.08 (-0.14 to -0.01)
2SMR-MAGIC-MR_Egger
-0.17 (-0.33 to 0.00)
2SMR-MAGIC-MR_Egger_SiMEX
-0.15 (-0.32 to 0.02)
-0.375 -0.25 -0.15 -0.05 0.05 0.15 0.25 0.35
SD increment per hr increase


Associations of L5 timing with glucose
Methods
Estimates
1SMR-2SLS
-0.10 (-0.24 to 0.04)
1SMR-CC-IVW
-0.07 (-0.18 to 0.03)
1SMR-CC-MR_Egger
0.00 (-0.22 to 0.23)
1SMR-CC-LADreg
-0.07 (-0.26 to 0.12)
2SMR-UKB-IVW
0.00 (-0.05 to 0.06)
2SMR-UKB-WM
0.03 (-0.03 to 0.10)
2SMR-UKB-MR_Egger
0.01 (-0.11 to 0.12)
2SMR-UKB-MR_Egger_SiMEX
0.01 (-0.11 to 0.12)
2SMR-MAGIC-IVW
0.02 (-0.03 to 0.07)
2SMR-MAGIC-WM
0.04 (-0.01 to 0.10)
2SMR-MAGIC-MR_Egger
0.06 (-0.03 to 0.15)
2SMR-MAGIC-MR_Egger_SiMEX
0.05 (-0.03 to 0.13)
-0.275 -0.2 -0.125 -0.05 0 0.05 0.1 0.15 0.2
SD increment per hr increase


Associations of M10 timing with glucose
Methods
Estimates
1SMR-2SLS
-0.32 (-0.67 to 0.03)
1SMR-CC-IVW
NA (NA to NA)
1SMR-CC-MR_Egger
NA (NA to NA)
1SMR-CC-LADreg
NA (NA to NA)
2SMR-UKB-IVW
0.09 (-0.09 to 0.27)
2SMR-UKB-WM
NA (NA to NA)
2SMR-UKB-MR_Egger
NA (NA to NA)
2SMR-UKB-MR_Egger_SiMEX
NA (NA to NA)
2SMR-MAGIC-IVW
0.04 (-0.11 to 0.18)
2SMR-MAGIC-WM
NA (NA to NA)
2SMR-MAGIC-MR_Egger
NA (NA to NA)
2SMR-MAGIC-MR_Egger_SiMEX
NA (NA to NA)
-0.5 0 0.5
SD increment per hr increase


Associations of sleep fragmentation with glucose
Methods
Estimates
1SMR-2SLS
0.01 (-0.01 to 0.04)
1SMR-CC-IVW
0.01 (-0.01 to 0.04)
1SMR-CC-MR_Egger
0.07 (-0.05 to 0.19)
1SMR-CC-LADreg
0.01 (-0.01 to 0.04)
2SMR-UKB-IVW
0.00 (-0.01 to 0.02)
2SMR-UKB-WM
0.01 (-0.01 to 0.03)
2SMR-UKB-MR_Egger
0.07 (-0.01 to 0.16)
2SMR-UKB-MR_Egger_SiMEX
0.11 (0.00 to 0.23)
2SMR-MAGIC-IVW
-0.01 (-0.02 to 0.00)
2SMR-MAGIC-WM
-0.01 (-0.02 to 0.01)
2SMR-MAGIC-MR_Egger
0.01 (-0.05 to 0.06)
2SMR-MAGIC-MR_Egger_SiMEX
0.01 (-0.06 to 0.09)
-0.075 -0.0250 0.025 0.075 0.125 0.175
SD increment per fragmentation (times) increase


Associations of sleep efficiency with glucose
Methods
Estimates
1SMR-2SLS
0.02 (-0.01 to 0.05)
1SMR-CC-IVW
0.01 (-0.01 to 0.04)
1SMR-CC-MR_Egger
-0.01 (-0.03 to 0.02)
1SMR-CC-LADreg
0.01 (-0.02 to 0.04)
2SMR-UKB-IVW
-0.01 (-0.02 to 0.01)
2SMR-UKB-WM
-0.01 (-0.02 to 0.01)
2SMR-UKB-MR_Egger
-0.02 (-0.05 to 0.01)
2SMR-UKB-MR_Egger_SiMEX
-0.02 (-0.05 to 0.01)
2SMR-MAGIC-IVW
-0.01 (-0.02 to 0.01)
2SMR-MAGIC-WM
-0.01 (-0.02 to 0.00)
2SMR-MAGIC-MR_Egger
-0.02 (-0.04 to 0.01)
2SMR-MAGIC-MR_Egger_SiMEX
-0.02 (-0.04 to 0.01)
-0.075 -0.05 -0.025 0 0.025 0.05
SD increment per % increase


The associations of SR sleep traits with HbA1c (1SMR-2SLS)
SR Sleepduration
Insomnia
Chronotype
Exposure
0.00
0.25
0.50
0.75
Outcome-HbA1c, Beta 95%CI (SD increasement)
dataset
All UKB
Sub-sample UKB


The associations of SR sleep traits with non-fasting glucose (1SMR-2SLS)
SR Sleepduration
Insomnia
Chronotype
Exposure
-0.1
0.0
0.1
0.2
0.3
0.4
Outcome-glucose, Beta 95%CI (SD increasement)
dataset
All UKB
Sub-sample UKB